CRISPR Therapeutics AG Earnings Estimates Up 3.5% in 30 Days

CRISPR Therapeutics AG (CRSP) has been on Zacks.com's list of most searched stocks. The stock has returned -7.6% over the past month versus the S&P 500's +1.6% change. Earnings estimates for the company are expected to decrease, with a loss of $1.31 per share for the current quarter and -$6.57 for the current fiscal year. The Zacks Rank for CRSP is #3 (Hold).

ARK Invest's ETFs, led by Cathie Wood, have shown significant activity in the tech and biotech sectors, particularly in CRISPR Therapeutics AG (CRSP). On Wednesday, August 27, 2025, ARKK, ARKW, and ARKF acquired 124,275 shares of CRISPR Therapeutics, investing approximately $6.82 million. This purchase follows a pattern of consistent buying in CRISPR, signaling a bullish stance on the gene-editing company's future [1].

CRISPR Therapeutics reported its Q2 2025 earnings on August 4, 2025, with an EPS of -$1.29, beating analysts' consensus estimates of -$1.47 by $0.18. Quarterly revenue rose 72.5% year-over-year to $0.89 million, below analyst estimates of $6.44 million. The company's trailing EPS is -$5.43, with earnings expected to grow next year from -$5.16 to -$4.03 per share [2].

ARK's strategic focus on innovative and disruptive companies in the technology and biotech industries is evident. While ARK increased its stake in CRISPR, it sold shares of DraftKings Inc (NASDAQ:DKNG) and Roku Inc (NASDAQ:ROKU), reducing its exposure to these companies [1].

Investors tracking ARK's movements will note the ETF's strategic shifts, which offer insight into Cathie Wood's investment strategy. ARK's focus on CRISPR highlights the potential growth areas in the biotech sector, while its divestments indicate areas where it is choosing to cut back.

References:
[1] https://www.investing.com/news/company-news/cathie-woods-ark-etf-bolsters-bitmine-and-crispr-stock-holdings-93CH-4213655
[2] https://www.marketbeat.com/stocks/NASDAQ/CRSP/earnings/